EOG Resources Inc vs Novo Nordisk A/S — how do they compare? EOG Resources Inc trades at $141.6 (market cap $75.22B), while Novo Nordisk A/S trades at $46 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.8× EOG Resources Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| EOG | NVO | |
|---|---|---|
Market Cap | $75.22B | $207.85B |
Sector | Energy | Health |
52-Week High | $149.89 | $63.98 |
52-Week Low | $101.78 | $35.29 |
Enterprise Value | $78.56B | $222.55B |
Dividend Yield | 2.85% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $142.22, up 5.55% today, with strong earnings beats in recent quarters and a bullish technical signal. The stock shows robust profitability with a 25.81% net income margin and attractive valuation metrics, including a P/E of 11.16. Recent news highlights operational strength and institutional buying interest, supporting positive momentum.
The outlook remains favorable with a consensus price target of $157.88, indicating potential upside. Key risks include oil price volatility and capital expenditure intensity, but disciplined cost controls and shareholder returns provide stability. The stock presents a compelling opportunity for growth-oriented investors seeking energy exposure.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Trailing returns across standard periods
Latest headlines on both assets
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →